Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$100.94 USD

100.94
684,123

+0.06 (0.06%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $101.05 +0.11 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (51 out of 244)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base

by Zacks Equity Research

Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.

    Zacks Equity Research

    Envision Healthcare Continues to Expand Physician Services

    by Zacks Equity Research

    Envision Healthcare's (EVHC) numerous acquisitions and management changes are aimed at growing its physician services segment.

      Zacks Equity Research

      Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now

      by Zacks Equity Research

      The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.

        Zacks Equity Research

        STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat

        by Zacks Equity Research

        STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.

          Zacks Equity Research

          Here's Why You Should Invest in Orthofix International Now

          by Zacks Equity Research

          Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.

            Zacks Equity Research

            Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?

            by Zacks Equity Research

            AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.

              Zacks Equity Research

              Omnicell (OMCL) Gains on Product Launches, Global Expansion

              by Zacks Equity Research

              The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.

                Zacks Equity Research

                Align Technology (ALGN) Prospects Bright, Competition Rife

                by Zacks Equity Research

                Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.

                  Zacks Equity Research

                  PetMed Express Optimistic on New Orders Amid Stiff Rivalry

                  by Zacks Equity Research

                  PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.

                    Zacks Equity Research

                    Anthem to Boost Medicare in Florida With HealthSun Buyout

                    by Zacks Equity Research

                    Anthem's (ANTM) inorganic growth continues to boost its top line. It strategically deploys capital in acquisitions to position its Medicare business for further growth.

                      Zacks Equity Research

                      Medtronic Advances in Pain Therapy With U.S. Intellis Launch

                      by Zacks Equity Research

                      We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.

                        Zacks Equity Research

                        Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

                        by Zacks Equity Research

                        The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.

                          Zacks Equity Research

                          Amedisys or Chemed: Which is a Better Investment Choice?

                          by Zacks Equity Research

                          After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).

                            Zacks Equity Research

                            Why Should Investors Add Amedisys (AMED) to Their Portfolio?

                            by Zacks Equity Research

                            Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.

                              Zacks Equity Research

                              Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now

                              by Zacks Equity Research

                              IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.

                                Zacks Equity Research

                                Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?

                                by Zacks Equity Research

                                Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.

                                  Zacks Equity Research

                                  Here's Why You Should Add Chemed (CHE) to Your Portfolio

                                  by Zacks Equity Research

                                  Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.

                                    Zacks Equity Research

                                    Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now

                                    by Zacks Equity Research

                                    BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.

                                      Zacks Equity Research

                                      Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy

                                      by Zacks Equity Research

                                      The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.

                                        Zacks Equity Research

                                        Boston Scientific MultiSENSE Study on HeartLogic Positive

                                        by Zacks Equity Research

                                        Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.

                                          Zacks Equity Research

                                          Becton, Dickinson Ultra-Fine Needle to Improve Diabetic Care

                                          by Zacks Equity Research

                                          Becton, Dickinson and Company's (BDX) latest micro pen needle will enhance the scope of its Diabetic Care unit.

                                            Zacks Equity Research

                                            Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1

                                            by Zacks Equity Research

                                            Neogen (NEOG) rides high on balanced growth across all business segments.

                                              Zacks Equity Research

                                              Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5

                                              by Zacks Equity Research

                                              Varian Medical (VAR) is consistently trying to turn around its Oncology Systems business.

                                                Zacks Equity Research

                                                Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?

                                                by Zacks Equity Research

                                                Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.

                                                  Zacks Equity Research

                                                  5 MedTech Stocks to Pick for Stellar Returns

                                                  by Zacks Equity Research

                                                  While the MedTech industry has been grappling with multiple issues, these stocks with high growth potential can be great bets.